Develops non-hormonal contraceptives and antimicrobials for women's reproductive health.
Jun 2026Revenue $18.0M/yrExpenses $20.8M/yr
No trendCash runway ≈ 3.1 years from Mar 2026
Figures by year
When will Evofem Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $18.0M and expenses $20.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $20.2M | $16.8M | $3.37M |
| Dec 2024 | $19.4M | $27.0M | −$7.68M |
| Dec 2023 | $18.2M | $36.1M | −$17.8M |
| Dec 2022 | $16.8M | $101M | −$84.1M |
| Dec 2021 | $8.24M | $175M | −$167M |
| Dec 2020 | $446K | $104M | −$104M |
| Dec 2019 | $0.00 | $52.7M | −$52.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.